R
Robert J. Ellis
Researcher at Princess Alexandra Hospital
Publications - 29
Citations - 283
Robert J. Ellis is an academic researcher from Princess Alexandra Hospital. The author has contributed to research in topics: Nephrectomy & Kidney disease. The author has an hindex of 8, co-authored 29 publications receiving 168 citations. Previous affiliations of Robert J. Ellis include Translational Research Institute & University of Queensland.
Papers
More filters
Journal ArticleDOI
Indoxyl sulphate and kidney disease: Causes, consequences and interventions
Robert J. Ellis,David M. Small,David A. Vesey,David A. Vesey,David W. Johnson,David W. Johnson,Ross S Francis,Luis Vitetta,Glenda C. Gobe,Christudas Morais +9 more
TL;DR: This review focuses on indoxyl sulphate (IS), a protein‐bound, tryptophan‐derived metabolite that is generated by intestinal micro‐organisms (microbiota) and demonstrates an association between IS accumulation and increased fibrosis, and oxidative stress.
Journal ArticleDOI
Allograft failure in kidney transplant recipients whose primary kidney disease was anca-associated vasculitis
L. Kuhnel,N. Maizels,Carmel M. Hawley,David W. Johnson,Glenda C. Gobe,Ross S Francis,Robert J. Ellis +6 more
TL;DR: Bacterial DNA and toxins were discovered in virtual all severely ill COVID-19 pneumonia patients, raising a previously unrecognized concern for significant contribution of bacterial products in the pathogenesis of this disease.
Journal ArticleDOI
Indoxyl Sulfate Induces Apoptosis and Hypertrophy in Human Kidney Proximal Tubular Cells.
Robert J. Ellis,Robert J. Ellis,David M. Small,David M. Small,Keng Lim Ng,Keng Lim Ng,David A. Vesey,David A. Vesey,Luis Vitetta,Ross S Francis,Ross S Francis,Glenda C. Gobe,Christudas Morais +12 more
TL;DR: The results of this study suggest that IS directly induced a pro-inflammatory and pro-fibrotic phenotype in proximal tubular cells and demonstrates that IS may play a role in the progression of chronic kidney disease.
Journal ArticleDOI
Cabozantinib for the Management of Metastatic Clear Cell Renal Cell Carcinoma.
TL;DR: This review briefly summarises how cabozantinib fits into current treatment paradigms for the management of advanced renal cell carcinoma.
Journal ArticleDOI
A Simple Clinical Tool for Stratifying Risk of Clinically Significant CKD after Nephrectomy: Development and Multinational Validation.
Robert J. Ellis,Sharon J. Del Vecchio,Kevin M Gallagher,Danielle N. Aliano,Neil Barber,Damien M Bolton,Etienne T S Chew,Jeff S. Coombes,Michael Coory,Ian D. Davis,James Donaldson,Ross S Francis,Graham G. Giles,Glenda C. Gobe,Carmel M. Hawley,David W. Johnson,David W. Johnson,David W. Johnson,Alexander Laird,Steve Leung,Manar Malki,David J. T. Marco,Alan McNeill,Rachel E. Neale,Keng Lim Ng,Simon Phipps,Grant D. Stewart,Victoria White,Simon Wood,Susan J. Jordan +29 more
TL;DR: A simple scoring system can reproducibly stratify postnephrectomy CKD risk on the basis of readily available parameters and may be weighed against other considerations when planning management of kidney tumors and help inform shared decision making between clinicians and patients.